Friday, 20 Sep 2019

You are here

Factors That Contribute to Uveitis in SpA

We know that uveitis is an extra-articular manifestation of SpA but what remains unclear is if there are any factors that may play a role in the development of uveitis. One group sought to understand these issues.

Dr. Kasifoglu et al sought to understand possible risk factors by looking at age, gender, duration of illness, BMI, educational status, smoking habits, SpA clinical findings and co-morbid disease, HLA B27 status, acute phase responses, VAS pain, VAS global, VAS fatigue, BASDAI and BASFI scores, swollen and tender joint counts and XR findings retrospectively.

The study looked at a total of 2359 SpA patients (2096 with axSPA, 1249 with AS, 100 with nr-axSpA, 179 with PsA, 50 with peripheral SPA and 51 with enteropathic arthritis.) Overall, 269 (11.4%) patients had experienced one or more episodes of uveitis. The median age of uveitis was 36 year old, with the start of SpA symptoms 6.8 years prior to uveitis. The median number of “attacks” was 2 (1-4) and were typically unilateral (78.9%.)   19/184 (10.3%) patients had permanent damage to the eye. These patients had more frequent attacks and had a tendency for bilateral eye involvement.


It appears that genetic background, radiographic severity of disease, presence of enthesis, and particularly disease duration may be related with uveitis. Although uveitis is usually self-limited, almost 10% of SpA patients may have permanent eye damage.

Add new comment

More Like This

NSAID Use Linked With Hypertension in Ankylosing Spondylitis

Continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) among patients with ankylosing spondylitis (AS) was associated with the development of incident hypertension, a prospective cohort study found.

Anti-IL-23 Beats IL-17 in Plaque Psoriasis

Lancet reports a head-to-head trial of antibodies against interleukin (IL)-23 and IL-17A in patients with moderate-to-severe psoriasis favored guselkumab with superior PASI 90 responses at week 48 (compared to secukinumab).

Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)

The FDA has approved the IL-17A inhibitor Taltz (ixekizumab) for the treatment of adults with active ankylosing spondylitis (AS: also known as radiographic axial spondyloarthritis).  

The recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.  The updated package insert can be found here.

ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis

The American College of Rheumatology (ACR), in partnership with the Spondylitis Association of America (SAA) and the Spondyloarthritis Research and Treatment Network (SPARTAN), released the 2019 Update of the Recommendations for the Treatment of Ankylosing Spondylitis (AS) and Nonradiographic Axial Spondyloarthritis (nr-axSpA).

Skyrizi Outduels Humira in Psoriasis

A head-to-head trial has shown that risankizumab was significantly superior to adalimumab in providing skin clearance (PASI90) in patients with moderate-to-severe plaque psoriasis, with no difference in safety signals between the two agents.